ストックスクリーナーアプリを入手
6.24
10.44%
0.59
アフターアワーズ：
6.22
-0.02
-0.32%
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit - PR Newswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - globenewswire.com
ARS Pharmaceuticals (NASDAQ: SPRY) CCO files first insider report with no shares - Stock Titan
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.6% HigherHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact Levi & Korsinsky - globenewswire.com
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmace - The National Law Review
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
2026-08-16 | SPRY DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ARS Pharmaceuticals Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:SPRY | Press Release - Stockhouse
ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen - Sahm
Analysts Have Lowered Expectations For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Its Latest Results - simplywall.st
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuti - The National Law Review
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit - timothysykes.com
Cantor Fitzgerald Remains a Buy on ARS Pharmaceuticals (SPRY) - The Globe and Mail
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
(SPRY) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings - MarketBeat
Attention Long-Term Shareholders of ARS Pharmaceuticals, - globenewswire.com
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals earnings missed by $0.13, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ - The National Law Review
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action DeadlineContact the Firm Before October 5, 2026 - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results - Investing News Network
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report - Investing.com
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings - Quiver Quantitative
ARS Pharma Q2 Results: Revenue up 114% YoY, net loss widens - scanx.trade
ARS Pharmaceuticals (Nasdaq: SPRY) doubles Q2 2026 revenue but posts larger loss - Stock Titan
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY - TMX Newsfile
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) - TMX Newsfile
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ARS Pharmaceuticals, Inc. ... - Caledonian Record
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings - Yahoo Finance
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earni - GuruFocus
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Sahm
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - Barchart.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals Investors Face October Lawsuit Deadline - stl.news
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - ycharts.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - globenewswire.com
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Eyeing a 352% Potential Upside in Biotechnology - DirectorsTalk Interviews
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASD - The National Law Review
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit ... - Caledonian Record
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - globenewswire.com
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals - globenewswire.com
SPRY Class Action ReminderRobbins LLP Reminds Investors - globenewswire.com
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, - GlobeNewswire
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc. - Morningstar
SPRY Deadline Alert: The Gross Law Firm Reminds ARS - GlobeNewswire
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):